Ibrutinib (PCI-32765) is an inhibitor of BTK, YES, and other SRC tyrosine kinases. Provided as 5mg of dry powder.
Ibrutinib (PCI-32765, Imbruvica) is an FDA approved drug that targets B-cell malignancies and is approved for treatment of mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom's macroglobulinemia. Ibrutinib is an orally-bioavailable compound that is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK). Also inhibits YES and other SRC family tyrosine kinases. Provided as 5mg of dry powder.
| Marque | DiscoverX |
|---|---|
| Réf. B-LABO | BL-RE-170186 |
| Réf. fabricant | 17362559 |
| Quantité | 5 mg |
